

Please type a plus sign (+) inside this box → ☐

(Modified) PTO/SB/21 (6-98)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

6

Application Number

10/092,640

Filing Date

March 4, 2002

First Named Inventor

Marks, James D.

Group Art Unit

1642

Examiner Name

Bansal, G.

Attorney Docket Number

407T-897221US

ENCLOSURES (check all that apply)

- ☐ Fee Transmittal Form
☐ Fee Attached
☐ Amendment / Response
☐ After Final
☐ Affidavits/declaration(s)
☐ Extension of Time Request
☐ Express Abandonment Request
☒ Information Disclosure Statement
☐ Certified Copy of Priority Document(s)
☐ Response to Missing Parts/ Incomplete Application
☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Assignment Papers (for an Application)
☐ Drawing(s)
☐ Licensing-related Papers
☐ Petition Routing Slip (PTO/SB/69) and Accompanying Petition
☐ Petition to Convert to a Provisional Application
☐ Power of Attorney, Revocation Change of Correspondence Address
☐ Terminal Disclaimer
☐ Small Entity Statement
☐ Request for Refund

- ☐ After Allowance Communication to Group
☐ Appeal Communication to Board of Appeals and Interferences
☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
☐ Proprietary Information
☐ Status Letter
☒ Additional Enclosure(s) (please identify below):

1449's From Parent Application receipt acknowledgment postcard

Authorization to Charge Deposit Account

Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.

Remarks

RECEIVED

JAN 08 2003

TECH CENTER 1600/2900

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name

Jonathan Alan Quine, Reg. No. 41,261, Quine Intellectual Property Law Group P.C.

Signature

Jonathan Alan Quine

Date

January 2, 2003

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: January 2, 2003

Typed or printed name

Amelia Groth

Signature

Amelia Groth

Date

January 2, 2003




RECEIVED
JAN 9 6 2003
TECH CENTER 1600/2900

I hereby certify that this correspondence is
being deposited with the United States
Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents,
Washington, D.C. 20231,
On January 2, 2003

Quine Intellectual Property Law Group, P.C.

By 
Amella Groth

Attorney Docket No. 407T-897221US
Client Ref. 95-276-4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Marks, James D., *et al.*

Application No.: 10/092,640

Filed: March 4, 2002

For: NOVEL HIGH AFFINITY HUMAN
ANTIBODIES TO TUMOR ANTIGENS

Examiner: Bansal, G.

Art Unit: 1642

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR § 1.97 and
§ 1.98

Assistant Commissioner for Patents
Washington, D.C. 20231


Sir:

The references cited on the attached PTO-1449 form are being called to the attention of the Examiner to make of record references cited in parent application USSN 09/315,574 filed May 20, 1999. Pursuant to 37 CFR § 1.98(d), copies of references cited in parent application USSN 09/315,574 filed May 20, 1999 are not provided. However the applicants will gladly provide fresh copies of any references requested by the Examiner. It is respectfully requested that the cited information on the attached 1449 form(s) be expressly considered during the prosecution of this application, and that references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, reading "Jonathan Alan Quine". The signature is written in a cursive, flowing style.

Jonathan Alan Quine
Reg. No. 41,261

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P.O. Box 458
Alameda, CA 94501
Tel: (510) 337-7871
Fax: (510) 337-7877

JAQ:ag

FORM PT01449
(REV. 8-83)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

2500.142US2

SERIAL NO.

09/315,574

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary) JAN 0 / 2001

APPLICANT

JAMES D. MARKS et al.

FILED

May 20, 1999

GROUP

1643

U. S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
A1	5 1 6 9 7 7 4	12/72	Frankel et al.			

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANS.? (YES/NO)
B1 92 / 2 2 6 5 3	12/92	PCT			Yes

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

- | | |
|----|---|
| C1 | Huston, et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ", Proceedings of the National Academy of Sciences, Vol. 85, August 1988, pp. 5879-5883. |
| C2 | Vallera Daniel A., ""Immunotoxins: Will Their Clinical Promise be Fulfilled", Blood: The Journal of The Americal Society of Hematology, Vol. 83, No. 2, January 15, 1994, pp. 309-317. |
| C3 | Trail, et al., "Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates", Science, July 9, 1993, Vol. 261, pp. 212-215. |
| C4 | Weiner, et al., Phase I Evaluation of an Anti-Breast Carcinoma Monoclonal Antibody 260F9-Recombinant Ricin a Chain Immunoconjugate", Cancer Research, Vol. 49, July 15, 1989, pp. 4062-4067. |
| C5 | Riethmuller, et al., "Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers", Current Opion in Immunology, 1992, Vol. 4, pp. 647-655. |
| C6 | Brinkmann, et al., "A recombinant immunotoxin that is active on prostate cancer cells and that is composed of the Fv region of monoclonal antibody PR1 and a truncated form of <i>Pseudomonas</i> exotoxin", Proceedings of the National Academy of Sciences, January 1993, Vol. 90, pp. 547-551. |
| C7 | Colcher, et al., "Radioimmunolocalization of Human Carcinoma Xenografts with B72.3 Second Generation Monoclonal Antibodies", Cancer Research, August 15, 1988, Vol. 48, pp. 4597-4603. |
| C8 | Gallinger, et al., "Comparative Dual Label Study of First and Second Generation Antiumor-associated Glycoprotein-72 Monoclonal Antibodies in Colorectal Cancer Patients", Cancer Research, January 15, 1993, Vol. 53, pp. 273-278. |

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

JAN 08 2003


TECH CENTER 1600/2900

FORM PT01449 (REV. 8-83)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 2500.142US2		SERIAL NO. 09/315,574	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANT JAMES D. MARKS et al.			
				FILED May 20, 1999		GROUP 1643	
U. S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent pages, Etc.)</i>							
	C9	Adams, et al., "Highly Specific <i>in Vivo</i> Tumor Targeting by Monovalent and Divalent Forms of 741F8 Anti-c-erbB-2 Single Chain Fv.					
	C10	Hoogenboom, et al., "Building Antibodies from their Genes", Immunological Reviews, 1992, No. 130, pp. 41-68.					
	C11	Marks, et al., "By-passing Immunization Human: Human antibodies from V-gene Libraries Displayed on Phage", Journal of Mol. Biology, 1991, Vol. 222, pp. 581-597.					
	C12	Marks, et al., "By-passing Immunization Human: Building High Affinity Human Antibodies by Chain Shuffling", Bio/Technology, July 1992, Vol. 10., pp. 779-783.					
	C13	Hawkins, et al., "Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation", Journal of Mol. Biology, 1992, Vol. 226, pp. 889-896.					
	C14	Reichmann, et al., "Phage Display and Selection of a Site-Directed Randomized Single-Chain Antibody Fv Fragment for Its Affinity Improvement", Biochemistry, 1993, Vol. 32, pp. 8848-8855.					
	C15	McCafferty, et al., "Phage antibodies: filamentous phage displaying antibody variable domains", Nature, December 6, 1990, Vol. 348, pp. 552-554.					
	C16	Griffiths, et al., "Human anti-self antibodies with high specificity from phage display libraries", EMBO Journal, 1993, Vol. 12, No. 2, pp. 725-734.					
	C17	Clackson, et al., "Making antibody fragments using phage display libraries", Nature, August 15, 1991, Vol. 352, pp. 624-628.					
	C18	Group, E.B.C.T.C., "Systemic Treatment of Early Breast Cancer by Hormonal Cytotoxic, or immune therapy, Lancet, 1992, Vol. 339, pp. 1-15.					
	C19	Allred, et al., "Overexpression of HER-2/neu and its Relationship with other prognostic factors change during the progression of in situ to invasive breast cancer", Human Pathology, September 1992, Vol. 23, No. 9, pp. 974-979.					
EXAMINER					DATE CONSIDERED		
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

RECEIVED

JAN 08 2003

TELETYPE UNIT 1600/2900

FORM PT01449 (REV. 8-83)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 2500.142US2		SERIAL NO. 09/315,574	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANT JAMES D. MARKS et al.			
				FILED May 20, 1999		GROUP 1643	
U. S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent pages, Etc.)</i>							
	C20	Slamon, et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene", Science, January 9, 1987, Vol. 235, pp. 177-182.					
	C21	Carter, et al., "Towards an immunotherapy for p185HER2 overexpressing tumors", Antigen & Antibody Engineering in Breast Cancer Diagnosis, 1994, pp. 83-94.					
	C22	Shepard, et al., "Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogenic to the Clinic", Journal of Clinical Immunology, 1991, Vol. 11, No. 3, pp. 117-127.					
	C23	Soderlind, et al., "Phage Display Technology in Antibody Engineering: Design of Phagemid Vectors and <i>in vitro</i> Maturation Systems", Immunological Reviews, 1992, No. 130, pp. 109-124.					
	C24	Borrebaeck Carl A.K., "Strategy for the production of human monoclonal antibodies using <i>in vitro</i> activated B cells", Journal of Immunological Methods, Vol. 123, 1989, pp. 157-165.					
	C25	Disis, et al., "Existent T-Cell and Antibody Immunity to HER-2/neu Protein in Patients with Breast Cancer", Cancer Research, Vol. 54, January 1, 1994, pp. 16-20.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

RECEIVED

JAN 0 8 2003

TECH CENTER 1600/2900